Evidence map›Paper›PMID 34864501›Full record

ArticleESMO open2021

Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

M Reck, T-E Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, E Richardet, J Bennouna, E Felip, O Juan-Vidal and 17 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 20 institutions in 11 countries.

M ReckDepartment of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de.
T-E CiuleanuDepartment of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.
M CoboDepartment of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
M SchenkerDepartment of Oncology, SF Nectarie Oncology Center, Craiova, Romania.
B ZurawskiDepartment of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland.
J MenezesDepartment of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
E RichardetDepartment of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina.
J BennounaDepartment of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France.
E FelipDepartment of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
O Juan-VidalDepartment of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain.
A AlexandruDepartment of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania.
H SakaiDepartment of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
A LinguaDepartment of Medical Oncology, Instituto Medico Rio Cuarto, SA, Córdoba, Argentina.
F ReyesDepartment of Medical Oncology, Fundación Arturo López Pérez, Santiago, Metropolitana, Chile.
P-J SouquetDepartment of Pneumology, Hôpital Lyon Sud, Lyon, Pierre Bénite, France.
P De MarchiDepartment of Oncology, Barretos Cancer Hospital, Barretos, Brazil.
C MartinDepartment of Thoracic Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
M PérolDepartment of Thoracic Oncology, Léon Bérard Cancer Center, Lyon, France.
A ScherpereelDepartment of Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France.
S LuDepartment of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
L Paz-AresDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain.
D P CarboneDepartment of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA.
A MemajBristol Myers Squibb, Princeton, USA.
S MarimuthuBristol Myers Squibb, Princeton, USA.
X ZhangBristol Myers Squibb, Princeton, USA.
P TranBristol Myers Squibb, Princeton, USA.
T JohnDepartment of Medical Oncology, Austin Hospital, Heidelberg, Australia.
Bristol-Myers Squibb (United States) · USAustin Hospital · AUCentre de Recherche en Cancérologie de Lyon · FRCentre Hospitalier Universitaire de Lille · FRFundación Arturo López Pérez · CLGerman Center for Lung Research · DEHôpital Lyon Sud · FRHospital de Câncer de Barretos · BRHospital Nossa Senhora da Conceição · BRHospital Universitari i Politècnic La Fe · ESHospital Universitario 12 De Octubre · ESInserm · FRInstitute of Oncology Prof. Dr. Ion Chiricuta · ROInstituto Alexander Fleming · ARInstituto de Investigación Biomédica de Málaga · ESInstituto Médico Río Cuarto · ARInstituto Oncológico de Córdoba · ARInstitutul Oncologic Bucuresti · ROSaitama Cancer Center · JPShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34864501
PMCPMC8649668
OpenAlexW4200470371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.